Newsroom
Publication: UNITE4TB: a new consortium for clinical drug and regimen development for TB
The increasing clinical and public health challenge of multidrug-resistant TB has triggered renewed scientific activity in anti-TB drug development.
Launched in July 2021, UNITE4TB aims to set a new standard for anti-TB regimen development – upgrading current clinical trial methodology and enhancing the efficiency with which new regimens are delivered.
Find out more in this recent editorial authored by partners of the Consortium and published in the International Journal of Tuberculosis and Lung Disease.